ArticleFrontiers in psychology2026
Zoletil 50-induced mental and behavioral abnormalities: a case report and literature review.
Article in Frontiers in psychology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Zoletil 50, mixed with tiletamine and zolazepam, a veterinary anesthetic, has increasingly been used as a substitute drug by substance abusers in recent years. Recently, it has been found in China that tiletamine has been added to electronic cigarettes as a stimulant, highlighting the need for further evaluation of its safety. Case presentation: A 22-year-old, previously healthy, unmarried male presented to a psychiatric outpatient clinic with a 4-month history of progressive low mood, anhedonia, and feelings of detachment from self and surroundings (depersonalization/derealization). He reported recreational use of powdered Zoletil 50, insufflated approximately 1-2 times per week. Following repeated use, he began experiencing acute, paroxysmal episodes characterized by intense panic, terror, tachycardia, and palpitations, lasting 30-60 min. There was no significant past medical or psychiatric history. Physical examination was unremarkable. Routine blood tests, thyroid function, and ECG were within normal limits. Conclusion: The use of Zoletil 50 or electronic cigarettes containing tiletamine can lead to addiction, suicidal tendencies, depressed mood, panic attacks. Long-term use of Zoletil 50 may result in various psychiatric and behavioral symptoms, while overdose can be fatal. There is an urgent need for society to strengthen regulations and oversight in this regard.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.